• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.

作者信息

Molica Matteo, Zacheo Irene, Diverio Daniela, Alimena Giuliana, Breccia Massimo

机构信息

Department of Cellular Biotechnologies and Haematology, Sapienza University, Rome, Italy.

出版信息

Br J Haematol. 2015 Apr;169(1):148-50. doi: 10.1111/bjh.13184. Epub 2014 Oct 9.

DOI:10.1111/bjh.13184
PMID:25296902
Abstract
摘要

相似文献

1
Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.基线时p210和p190共表达的慢性髓性白血病患者的长期预后
Br J Haematol. 2015 Apr;169(1):148-50. doi: 10.1111/bjh.13184. Epub 2014 Oct 9.
2
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.至少持续 2 年完全分子缓解的慢性髓性白血病患者停止伊马替尼治疗：前瞻性、多中心停止伊马替尼（STIM）试验。
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.
3
BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.BAX/BCL-XL 基因表达比值与慢性髓性白血病的疾病进展呈负相关。
Blood Cells Mol Dis. 2010 Oct 15;45(3):192-6. doi: 10.1016/j.bcmd.2010.07.011. Epub 2010 Aug 21.
4
A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210 and P195 isoforms.一名双费城染色体阳性慢性髓性白血病患者，共表达P210和P195亚型。
Haematologica. 2018 Nov;103(11):e549-e552. doi: 10.3324/haematol.2018.192534. Epub 2018 Aug 9.
5
The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.伴有BCR-ABL的成人B淋巴细胞白血病谱系：分子诊断、细胞遗传学及临床实验室视角
Am J Hematol. 2008 Dec;83(12):901-7. doi: 10.1002/ajh.21291.
6
Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.伊朗慢性髓性白血病患者中BCR-ABL融合转录本的频率
Arch Iran Med. 2008 May;11(3):247-51.
7
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.慢性粒细胞白血病中急性白血病相关的P190BCR-ABL的出现可能与疾病进展相关。
Leukemia. 1991 Mar;5(3):191-5.
8
Recent advances in molecular biology of chronic myeloid leukaemia: is the pathogenetic puzzle approaching solution?慢性髓性白血病分子生物学的最新进展：致病谜团是否即将解开？
Bone Marrow Transplant. 1989 Jan;4 Suppl 1:129-30.
9
[Detection of bcr/abl gene expression on bone marrow cell colonies in chronic myelogenous leukemia by reverse transcriptase-polymerase chain reaction].[应用逆转录-聚合酶链反应检测慢性粒细胞白血病骨髓细胞集落中的bcr/abl基因表达]
Hunan Yi Ke Da Xue Xue Bao. 1999;24(5):418-20.
10
Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.在一名对伊马替尼耐药的慢性髓性白血病患者中，通过针对BCR-ABL转录本的小干扰RNA（siRNA）对基因表达进行治疗性靶向。
Methods Mol Biol. 2009;487:451-66. doi: 10.1007/978-1-60327-547-7_22.

引用本文的文献

1
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia.ABL1酪氨酸激酶的结构与动力学及其在慢性髓性白血病中的重要作用
Arch Pharm (Weinheim). 2025 May;358(5):e70005. doi: 10.1002/ardp.70005.
2
Association of PARP1 Expression Levels and Clinical Parameters in Different Leukemic Subtypes With Translocation.PARP1表达水平与不同伴有易位的白血病亚型临床参数的关联
Cancer Diagn Progn. 2024 Sep 1;4(5):592-598. doi: 10.21873/cdp.10368. eCollection 2024 Sep-Oct.
3
Targeting BCR-ABL1-positive leukaemias: a review article.
靶向BCR-ABL1阳性白血病：一篇综述文章。
Camb Prism Precis Med. 2023 Mar 6;1:e21. doi: 10.1017/pcm.2023.9. eCollection 2023.
4
Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.在人类白血病中对 ABL 激酶的结构、调控和靶向作用的临床见解。
Int J Mol Sci. 2024 Mar 14;25(6):3307. doi: 10.3390/ijms25063307.
5
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.欧洲白血病网络实验室关于慢性髓性白血病诊断和管理的建议。
Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.
6
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.慢性髓性白血病的预后：基线因素、动态风险评估和新的见解。
Cells. 2023 Jun 23;12(13):1703. doi: 10.3390/cells12131703.
7
Bleeding Diathesis as the Initial Presentation of Chronic Myeloid Leukemia: A Case Series.以出血素质为首发表现的慢性髓系白血病：病例系列
Cureus. 2023 Apr 6;15(4):e37201. doi: 10.7759/cureus.37201. eCollection 2023 Apr.
8
Chronic Myelogenous Leukemia with Double Philadelphia Chromosome and Coexpression of p210 and p190 Fusion Transcripts.慢性髓性白血病伴双费城染色体和 p210 及 p190 融合转录本的共表达。
Genes (Basel). 2022 Mar 25;13(4):580. doi: 10.3390/genes13040580.
9
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.鉴定 p190-Bcr-Abl 慢性髓性白血病的特征揭示了特定的信号通路和治疗靶点。
Leukemia. 2021 Jul;35(7):1964-1975. doi: 10.1038/s41375-020-01082-4. Epub 2020 Nov 9.
10
Prognostic Significance of Transcript-Type in Chronic Myeloid Leukemia.转录本类型在慢性髓性白血病中的预后意义
Mediterr J Hematol Infect Dis. 2020 Sep 1;12(1):e2020062. doi: 10.4084/MJHID.2020.062. eCollection 2020.